- Home
- MYNZ vs PHGE Comparison
MYNZ vs PHGE Comparison
Compare MYNZ & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- PHGE
- Stock Information
- Founded
- MYNZ 2021
- PHGE 2015
- Country
- MYNZ Germany
- PHGE Israel
- Employees
- MYNZ N/A
- PHGE N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- PHGE Health Care
- Exchange
- MYNZ Nasdaq
- PHGE Nasdaq
- Market Cap
- MYNZ 11.2M
- PHGE 13.3M
- IPO Year
- MYNZ 2021
- PHGE N/A
- Fundamental
- Price
- MYNZ $4.83
- PHGE $0.77
- Analyst Decision
- MYNZ Hold
- PHGE Strong Buy
- Analyst Count
- MYNZ 2
- PHGE 2
- Target Price
- MYNZ N/A
- PHGE $13.50
- AVG Volume (30 Days)
- MYNZ 135.3K
- PHGE 110.1K
- Earning Date
- MYNZ 10-21-2024
- PHGE 11-14-2024
- Dividend Yield
- MYNZ N/A
- PHGE N/A
- EPS Growth
- MYNZ N/A
- PHGE N/A
- EPS
- MYNZ N/A
- PHGE N/A
- Revenue
- MYNZ $917,203.00
- PHGE N/A
- Revenue This Year
- MYNZ $21.95
- PHGE N/A
- Revenue Next Year
- MYNZ $30.77
- PHGE N/A
- P/E Ratio
- MYNZ N/A
- PHGE N/A
- Revenue Growth
- MYNZ 16.23
- PHGE N/A
- 52 Week Low
- MYNZ $0.18
- PHGE $0.48
- 52 Week High
- MYNZ $7.95
- PHGE $8.55
- Technical
- Relative Strength Index (RSI)
- MYNZ 53.87
- PHGE 56.75
- Support Level
- MYNZ $3.86
- PHGE $0.70
- Resistance Level
- MYNZ $6.81
- PHGE $0.80
- Average True Range (ATR)
- MYNZ 0.74
- PHGE 0.08
- MACD
- MYNZ -0.09
- PHGE 0.01
- Stochastic Oscillator
- MYNZ 32.88
- PHGE 60.76
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.